RT Journal Article
SR Electronic
T1 Patient-specific forecasting of post-radiotherapy prostate-specific antigen kinetics enables early prediction of biochemical relapse
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.07.22271524
DO 10.1101/2022.03.07.22271524
A1 Lorenzo, Guillermo
A1 Muzio, Nadia di
A1 Deantoni, Chiara Lucrezia
A1 Cozzarini, Cesare
A1 Fodor, Andrei
A1 Briganti, Alberto
A1 Montorsi, Francesco
A1 Pérez-García, Víctor M.
A1 Gomez, Hector
A1 Reali, Alessandro
YR 2022
UL http://medrxiv.org/content/early/2022/03/09/2022.03.07.22271524.abstract
AB The detection of prostate cancer recurrence after external beam radiotherapy relies on the measurement of a sustained rise of serum prostate-specific antigen (PSA). However, this biochemical relapse may take years to occur, thereby delaying the delivery of a secondary treatment to patients with recurring tumors. To address this issue, here we propose to use patient-specific forecasts of PSA dynamics to early predict biochemical relapse. Our forecasts are based on mechanistic models of prostate cancer response to external beam radio-therapy, which are fit to patient-specific PSA data collected during standard post-treatment monitoring. Our results show a remarkable performance of our models in recapitulating the observed changes in PSA and yielding short-term predictions over approximately one year (cohort median RMSE of 0.10 to 0.47 ng/mL and 0.13 to 1.41 ng/mL, respectively). Additionally, we identify three model-based biomarkers that enable an accurate identification of biochemical relapse (AUC > 0.80) significantly earlier than standard practice (p < 0.01).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 838786. A.R. was partially supported by the MIUR-PRIN project XFAST-SIMS (No. 20173C478N). H.G. was partially funded by the Purdue Center for Cancer Research through a Concept Grant. V.M.P.G. is partially supported by the Spanish Ministerio de Ciencia e Innovacion (grant PID2019-110895RB-100, doi:10.13039/501100011033).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Anonymized patient data were retrospectively collected at Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele (IRCCSOSR, Milan, Italy). Ethics approval and informed consent waiver were obtained from the Internal Review Board at IRCCSOSR for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data and all original code are available online at Zenodo (https://doi.org/10.5281/zenodo.6277674). https://doi.org/10.5281/zenodo.6277674